Why the study?
Existing universal definitions of post-revascularization MI use biomarker thresholds of uncertain prognostic importance, risking inappropriate assessment of therapies, clinical care pathways, and physician competence.
Should a new definition of clinically relevant MI based on prognostically significant biomarker thresholds replace the universal definition of MI after coronary revascularization?
Should a new definition of clinically relevant MI based on prognostically significant biomarker thresholds replace the universal definition of MI after coronary revascularization?
Proposes a new, prognostically relevant definition of periprocedural MI after revascularization to better guide clinical trials, patient care, and quality assessment.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Widespread adoption of an MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence.”
“The biomarkers are elevating, they've not peaked. It's also very likely PCI worsens the extent of myocardial necrosis in STEMI, because it does not infrequently cause distal atherothrombotic embolization. But it's very difficult to pick it up.”
“There is a lot of debate and controversy about how we best define type 4a MIs, with previous studies like EXCEL and ISCHEMIA using their own definitions. Depending on the definition used, this can change the outcomes of these trials quite significantly. The aim of our group was to come together and to critically appraise the literature—what's been done in the field with respect to validating the type 4a MI definitions—as well as streamline the definition of major and minor myocardial injury.”
New MI definition may refine post-revascularization risk stratification; leaves open prospective validation before practice change.
Numerous definitions have been proposed for the diagnosis of myocardial infarction (MI) after coronary revascularization. The universal definition for MI designates post procedural biomarker thresholds for defining percutaneous coronary intervention (PCI)-related MI (type 4a) and coronary artery bypass grafting (CABG)-related MI (type 5), which are of uncertain prognostic importance. In addition, for both the MI types, cTn is recommended as the biomarker of choice, the prognostic significance of which is less well validated than CK-MB. Widespread adoption of a MI definition not clearly linked to subsequent adverse events such as mortality or heart failure may have serious consequences for the appropriate assessment of devices and therapies, may affect clinical care pathways, and may result in misinterpretation of physician competence. Rather than using an MI definition sensitive for small degrees of myonecrosis (the occurrence of which, based on contemporary large-scale studies, are unlikely to have important clinical consequences), it is instead recommended that a threshold level of biomarker elevation which has been strongly linked to subsequent adverse events in clinical studies be used to define a “clinically relevant MI.” The present document introduces a new definition for “clinically relevant MI” after coronary revascularization (PCI or CABG), which is applicable for use in clinical trials, patient care, and quality outcomes assessment.
No takes yet. Share an insight, caveat, or question.
Moussa et al. (2013) conducted a review in Myocardial infarction after coronary revascularization. New definition of clinically relevant myocardial infarction was evaluated. A new definition for clinically relevant myocardial infarction after coronary revascularization is proposed, utilizing biomarker thresholds strongly linked to subsequent adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: